Moreover, osteocalcin treatment substantially reduced multiple NASH components with robustly reduced expression of proinflammatory and profibrotic genes in the liver and proinflammatory genes in the white adipose tissue (42). The gene discussed is BGLAP; the disease is metabolic dysfunction-associated steatohepatitis.